Combined treatment of ETB-siRNA (20 nM) with anti-tumor drug, cisplatin (2.5 μM), drastically inhibited the cell growth of SAS in comparison to that in each single treatment (Fig. 5A). Here, EDNRB is linked to neoplasm.